These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19633474)

  • 21. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.
    Florescu M; Hasan B; Seymour L; Ding K; Shepherd FA;
    J Thorac Oncol; 2008 Jun; 3(6):590-8. PubMed ID: 18520796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
    Koyama N; Uchida Y
    Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
    Fuster LM; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [TRUST study: general practice relevant data on erlotinib in NSCLC].
    Knabl A
    Wien Med Wochenschr; 2007; 157(21-22):579-80. PubMed ID: 18157598
    [No Abstract]   [Full Text] [Related]  

  • 25. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
    Akerley W; Boucher KM; Bentz JS; Arbogast K; Walters T
    J Thorac Oncol; 2009 Feb; 4(2):214-9. PubMed ID: 19179899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
    Shi L; Tang J; Tong L; Liu Z
    Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
    Sandler A
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
    Pluquet E; Cadranel J; Legendre A; Faller MB; Souquet PJ; Zalcman G; Perol M; Fraboulet G; Oliveiro G; De Fraipont F; Quoix E; Lantuejoul S; Milleron B; Moro-Sibilot D
    J Thorac Oncol; 2010 Apr; 5(4):491-6. PubMed ID: 20195171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study.
    Arrieta O; Martinez-Barrera L; Treviño S; Guzman E; Castillo-Gonzalez P; Rios-Trejo MA; Flores-Estrada D; Téllez E; Gonzalez C; de la Cruz Vargas J; Gonzalez-De la Rosa CH; Hernandez-Pedro N; Morales-Barrera R; De la Garza J
    J Thorac Oncol; 2008 Aug; 3(8):887-93. PubMed ID: 18670307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib.
    Chen MJ; Zhong W; Zhang L; Zhao J; Li LY; Wang MZ
    Chin Med J (Engl); 2013 Jun; 126(12):2235-41. PubMed ID: 23786931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.
    Lee Y; Kim HY; Lee SH; Lim KY; Lee GK; Yun T; Han JY; Kim HT; Lee JS
    Clin Lung Cancer; 2014 Mar; 15(2):145-51. PubMed ID: 24342626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
    Motoshima K; Nakamura Y; Sano K; Ikegami Y; Ikeda T; Mizoguchi K; Takemoto S; Fukuda M; Nagashima S; Iida T; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1299-1304. PubMed ID: 24121455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.
    Petrelli F; Borgonovo K; Cabiddu M; Barni S
    Clin Lung Cancer; 2012 Mar; 13(2):107-14. PubMed ID: 22056888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
    Yamada K; Aono H; Hosomi Y; Okamoto H; Kato T; Komase Y; Nishikawa M; Azuma K; Takeoka H; Okuma Y; Nakahara Y; Sato A; Oba MS; Morita S; Kunitoh H; Watanabe K
    Eur J Cancer; 2015 Sep; 51(14):1904-10. PubMed ID: 26174465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
    J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.